Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the 'colonic brake' to gastric emptying

Gut

Volumn 39, Issue 2, 1996, Pages 267-272

  Nightingale, J M D ^a,c   Kamm, M A ^a   Van Der Sijp, J R M ^a   Ghatei, M A ^b   Bloom, S R ^b   Lennard Jones, J E ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Peptide hormones; Peptide YY; Satiety; Short bowel syndrome

Indexed keywords

CHOLECYSTOKININ; GASTRIN; GASTROINTESTINAL HORMONE; MOTILIN; NEUROTENSIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; SOMATOSTATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; JEJUNOSTOMY; MALE; PRIORITY JOURNAL; SATIETY; SHORT BOWEL SYNDROME; STOMACH EMPTYING; STOMACH PH;

EID: 0029833104     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.39.2.267     Document Type: Article

References (51)

1. Nightingale JMD, Lennard-Jones JE, Gertner DJ, Wood SR, Bartram CI. Colonic preservation reduces the need for parenteral therapy, increases the incidence of renal stones but does not change the high prevalence of gallstones in patients with a short bowel. Gut 1992; 33: 1493-7.
2. Nightingale JMD, Lennard-Jones JE, Walker ER, Farthing MJG. Jejunal efflux in short bowel syndrome. Lancet 1990; 336: 765-8.
3. Nightingale JMD, van der Sijp JRM, Kamm MA, Walker ER, Mather SJ, Britton KE, et al. Disturbed gastric emptying in the short bowel syndrome. Evidence for a 'colonic brake'. Gut 1993; 34: 1171-6.
4. Buxton B. Small bowel resection and gastric acid hypersecretion. Gut 1974; 15: 229-38.
5. Nightingale JMD, Bartram CI, Lennard-Jones JE. Length of residual small bowel after partial resection: correlation between radiographic and surgical measurements. Gastrointest Radiol 1991; 16: 305-6.
6. Bloom SR, Long RG. Radioimmunoassay of gut regulatory peptides. London: W B Saunders, 1982.
7. Adrian TE, Ferri G-L, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, Peptide YY. Gastroenterology 1985; 89: 1070-7.
8. Jansen JBMJ, Lamers CBHW. Radioimmunoassay of cholecystokinin in human tissue and plasma. Clin Chim Acta 1983; 131: 305-16.
9. Ali-Rachedi A, Varndell IM, Adrian TE, Gapp DA, Van Noorden S, Bloom SR, et al. Peptide YY (PYY) immunoreactivity is co-stored with glucagon-related immunoreactants in endocrine cells of the gut and pancreas. Histochemistry 1984; 80: 487-91.
10. Bottcher G, Sjolund K, Ekblad E, Hakanson R, Schwartz TW, Sundler F. Co-existance of peptide YY and glicentin immunoreactivity in endocrine cells of the gut. Regul Pept 1984; 8: 261-6.
11. Aponte GW, Fink AS, Meyer JH, Tatemoto K, Taylor IL. Regional distribution and release of peptide YY with fatty acids of different chain length. Am J Physiol 1985; 249: G745-50.
12. Adrian TE, Ballantyne GH, Longo WE, Bilchik AJ, Graham S, Basson MD, et al. Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut 1993; 34: 1219-24.
13. Adrian TE, Savage AP, Bacarese-Hamilton AJ, Wolfe K, Besterman HS, Bloom SR. Peptide YY abnormalities in gastrointestinal diseases. Gastroenterology 1986; 90: 379-84.
14. Adrian TE, Long RG, Fuessl HS, Bloom SR. Plasma peptide YY (PYY) in dumping syndrome. Dig Dis Sci 1985; 30: 1145-8.
15. Adrian TE, Savage AP, Fuessl HS, Wolfe K, Besterman HS, Bloom SR. Release of peptide YY (PYY) after resection of small bowel, colon or pancreas in man. Surgery 1987; 101: 715-9.
16. Andrews NJ, Irving MH. Human gut hormone profiles in patients with short bowel syndrome. Dig Dis Sci 1992; 37: 729-32.
17. Allen JM, Fitzpatrick ML, Yeats JC, Darcy K, Adrian TE, Bloom SR. Effect of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 1984; 30: 255-62.
18. Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987; 28: 166-70.
19. Spiller RC, Trotman IF, Adrian TE, Bloom SR, Misiewicz JJ, Silk DBA. Further characterisation of the 'ileal brake' reflex in man - effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY. Gut 1988; 29: 1042-51.
20. Adrian TE, Savage AP, Sagor GR, Allen JM, Bacarese-Hamilton AJ, Tatemoto K, et al. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 1985; 89: 494-9.
21. Bilchik AJ, Hines OJ, Adrian TE, McFadden DW, Berger JJ, Zinner MJ, et al. Peptide YY is a physiological regulator of water and electrolyte absorption in the canine small bowel in vivo. Gastroenterology 1993; 105: 1441-8.
22. Polak JM, Sullivan SN, Bloom SR, Buchan AMJ, Facer P, Brown MR, et al. Neurotensin in human intestine: radioimmunoassay and specific localisation in the N cell. Nature 1977; 270: 183-5.
23. Blackburn AM, Fletcher DR, Bloom SR, Christofides ND, Long RG, Fitzpatrick ML, et al. Effect of neurotensin on gastric function. Lancet 1980; i: 987-9.
24. Polak JM, Buchan AMJ. Motilin immunocytochemical localisation indicates possible molecular heterogeneity or the existence of a moulin family Gastroenterology 1979; 76: 1065-6.
25. Bryant MG, Bloom SR. Distribution of the gut hormones in the primate intestinal tract. Gut 1979; 20: 653-9.
26. Debas HT, Yamagishi T, Dryburgh JR. Motilin enhances gastric emptying of liquids in dogs. Gastroenterology 1977; 73: 777-80.
27. Christofides ND, Modlin IM, Fitzpatrick ML, Bloom SR. Effect of motilin on rate of gastric emptying and gut hormone release during breakfast. Gastroenterology 1979; 76: 903-7.
28. Christofides ND, Long RG, Fitzpatrick ML, McGregor GP, Bloom SR. Effect of motilin on gastric emptying of glucose and fat in humans. Gastroenterology 1981; 80: 456-60.
29. Baak LC, Jansen JBMJ, Biemond I, Lamers CBHW. Weekend treatment with 20 and 40 mg omeprazole: effect on intragastric pH, fasting and postprandial serum gastrin, and serum pepsinogens. Gut 1991; 32: 977-82.
30. Lanzon-Miller S, Pounder RE, Hamilton MR, Ball S, Chronos NAF, Raymond F, et al. Twenty-four hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Therap 1987; 1: 239-51.
31. Roberts CJC. Clinical pharmocokinetics of ranitidine. Clin Pharmacokinet 1984; 9: 211-21.
32. Kennedy HJ, Sarson DL, Bloom SR, Truelovc SC. Gut hormone responses in subjects with a permanent ileostomy. Digestion 1982; 24: 133-6.
33. Temperley JM, Stagg BH, Wyllie JH. Disappearance of gastrin and pentagastrin in the portal circulation, Gut 1971; 12: 372-6.
34. Becker HD, Reeder DD, Thompson JC. Extraction of circulating endogenous gastrin by the small bowel. Gastroenterology 1973; 65: 903-6.
35. Straus E, Gerson CD, Yalow RS. Hypersecretion of gastrin associated with the short bowel syndrome. Gastroenterology 1974; 66: 175-80.
36. Williams NS, Evans P, King RFGJ. Gastric acid secretion and gastrin production in the short bowel syndrome. Gut 1985; 26: 914-9.
37. Windsor CWO, Fejfar J, Woodward DAK. Gastric secretion after massive small bowel resection. Gut 1969; 10: 779-86.
38. Bloom SR, Polak JM. Somatostatin. BMJ 1987; 295: 288-9.
39. Nightingale JMD, Walker ER, Burnham WR, Farthing MJG, Lennard-Jones JE. Octreotide (a somatostatin analogue) improves the quality of life in some patients with a short intestine. Aliment Pharmacol Therap 1989: 3: 367-73.
40. Sturdevant RAL, Goetz H. Cholecystokinin both stimulates and inhibits human food intake. Nature 1976; 261: 713-5.
41. Muurahainen N, Kissileff HR, Derogatis AJ, Pi-Sunyer FX. Effects of cholecystokinin-octapeptide (CCK-8) on food intake and gastric emptying in man. Physiol Behav 1988; 44: 645-9.
42. Lieverse RJ, Jansen JBMJ, Masclee AAM, Lamers CBHW. Satiety effects of cholecystokinin in humans. Gastroenterology 1994; 106: 1451-4.
43. Porus RL. Epithelial hyperplasia following massive small bowel resection in man. Gastroenterology 1965; 48: 753-9.
44. Weinstein LD, Shoemaker CP, Hersh T, Wright HK. Enhanced intestinal absorption after small bowel resection in man. Arch Surg 1969; 99: 560-2.
45. Dowling RH, Booth CC. Functional compensation after small bowel resection in man: demonstration by direct measurement. Lancet 1966; ii: 146-7.
46. O'Keefe SJD, Shorter RG, Bennet WM, Haymond MW. Villous hyperplasia is uncommon in patients with massive intestinal resection. Gastroenterology 1992; 102: A231.
47. Gleeson MH, Bloom SR, Polak JM, Henry K, Dowling RH. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function, Gut 1971; 12: 773-82.
48. Bloom SR. An enteroglucagon tumour, Gut 1972; 13: 520-3.
49. Rudo ND, Rosenberg IH. Chronic glucagon administration enhances intestinal transport in the rat. Proc Soc Exp Biol Med 1973; 142: 521-5.
50. Miazza BM, Al-Mukhtar MYT, Salmerson M, Ghatei MA, Felce-Dachez M, Filali A, et al. Hyperenteroglucagonaemia and small intestinal mucosal growth after colonic perfusion of glucose in rats. Gut 1985; 26: 518-24.
51. de Miguel E, Gomez de Segura IA, Bonet H, Rodriguez Montes J A, Mata A. Trophic effects of neurotensin in massive bowel resection in the rat. Dig Dis Sci 1994; 39: 59-64.